FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232272478> ?p ?o ?g. }

• W4232272478 endingPage "S319" @default.
• W4232272478 startingPage "S318" @default.
• W4232272478 abstract "Abstract Background Ceftazidime–avibactam (CAZ-AVI) is a β-lactam/non-β-lactam β-lactamase inhibitor combination that can inhibit class A, C and some class D β-lactamases. Resistance caused by these β-lactamases often results in multidrug-resistance (MDR). This study evaluated the in vitro activity of CAZ-AVI and comparators against MDR Enterobacteriaceae and Pseudomonas aeruginosa isolates collected from patients in Latin America. Methods Nonduplicate clinical isolates were collected in 2016–2017 in 6 countries in Latin America. Susceptibility testing was performed using CLSI broth microdilution and interpreted using CLSI 2019 and FDA (tigecycline) breakpoints. MDR was defined as nonsusceptible (NS) (intermediate or resistant) to ≥3 of 7 sentinel drugs: amikacin, aztreonam, cefepime, levofloxacin, colistin, meropenem, and piperacillin–tazobactam. Results The activity of CAZ-AVI and comparators against all isolates and MDR subsets is shown in the table. MDR rates ranged from 28.4% among E. cloacae to 41.5% among K. pneumoniae. CAZ-AVI was active against >97% of Enterobacteriaceae isolates and maintained activity against >92% of MDR isolates of the examined species. No other tested drug consistently exceeded this activity. Among P. aeruginosa, CAZ-AVI was active against 87% of all isolates and 63% of MDR isolates; only colistin was more active. The two most common MDR phenotypes among Enterobacteriaceae were (1) NS to aztreonam, cefepime, and levofloxacin (n = 580, 41% of all MDR Enterobacteriaceae; 100% susceptible to CAZ-AVI) and (2) NS to aztreonam, cefepime, levofloxacin, and piperacillin–tazobactam (n = 301, 21% of all MDR isolates; 99.7% susceptible to CAZ-AVI). The two most common MDR phenotypes among P. aeruginosa were (1) NS to all sentinel drugs except colistin (n = 154, 33% of all MDR isolates; 30.5% susceptible to CAZ-AVI) and (2) NS to all drugs except colistin and amikacin (n = 97, 21% of all MDR isolates; 70.1% susceptible to CAZ-AVI). Conclusion These in vitro data suggest that CAZ-AVI can be an effective treatment option for infections caused by MDR Enterobacteriaceae and P. aeruginosa collected in Latin America. Disclosures All authors: No reported disclosures." @default.
• W4232272478 created "2022-05-12" @default.
• W4232272478 creator A5017159626 @default.
• W4232272478 creator A5020992600 @default.
• W4232272478 creator A5038009031 @default.
• W4232272478 creator A5066677972 @default.
• W4232272478 date "2019-10-01" @default.
• W4232272478 modified "2023-09-25" @default.
• W4232272478 title "706. In Vitro Activity of Ceftazidime–Avibactam and Comparator Agents Against MDR Enterobacteriaceae and Pseudomonas aeruginosa Collected in Latin America During the ATLAS Global Surveillance Program 2016–2017" @default.
• W4232272478 doi "https://doi.org/10.1093/ofid/ofz360.774" @default.
• W4232272478 hasPublicationYear "2019" @default.
• W4232272478 type Work @default.
• W4232272478 citedByCount "0" @default.
• W4232272478 crossrefType "journal-article" @default.
• W4232272478 hasAuthorship W4232272478A5017159626 @default.
• W4232272478 hasAuthorship W4232272478A5020992600 @default.
• W4232272478 hasAuthorship W4232272478A5038009031 @default.
• W4232272478 hasAuthorship W4232272478A5066677972 @default.
• W4232272478 hasBestOaLocation W42322724781 @default.
• W4232272478 hasConcept C104317684 @default.
• W4232272478 hasConcept C176947019 @default.
• W4232272478 hasConcept C2775933652 @default.
• W4232272478 hasConcept C2776968632 @default.
• W4232272478 hasConcept C2777027569 @default.
• W4232272478 hasConcept C2777050379 @default.
• W4232272478 hasConcept C2777406300 @default.
• W4232272478 hasConcept C2777637488 @default.
• W4232272478 hasConcept C2778193466 @default.
• W4232272478 hasConcept C2778910516 @default.
• W4232272478 hasConcept C2779259085 @default.
• W4232272478 hasConcept C2779375183 @default.
• W4232272478 hasConcept C2779631663 @default.
• W4232272478 hasConcept C2780416669 @default.
• W4232272478 hasConcept C2780950330 @default.
• W4232272478 hasConcept C4937899 @default.
• W4232272478 hasConcept C501593827 @default.
• W4232272478 hasConcept C523546767 @default.
• W4232272478 hasConcept C54355233 @default.
• W4232272478 hasConcept C547475151 @default.
• W4232272478 hasConcept C55493867 @default.
• W4232272478 hasConcept C71924100 @default.
• W4232272478 hasConcept C86803240 @default.
• W4232272478 hasConcept C89423630 @default.
• W4232272478 hasConcept C94665300 @default.
• W4232272478 hasConceptScore W4232272478C104317684 @default.
• W4232272478 hasConceptScore W4232272478C176947019 @default.
• W4232272478 hasConceptScore W4232272478C2775933652 @default.
• W4232272478 hasConceptScore W4232272478C2776968632 @default.
• W4232272478 hasConceptScore W4232272478C2777027569 @default.
• W4232272478 hasConceptScore W4232272478C2777050379 @default.
• W4232272478 hasConceptScore W4232272478C2777406300 @default.
• W4232272478 hasConceptScore W4232272478C2777637488 @default.
• W4232272478 hasConceptScore W4232272478C2778193466 @default.
• W4232272478 hasConceptScore W4232272478C2778910516 @default.
• W4232272478 hasConceptScore W4232272478C2779259085 @default.
• W4232272478 hasConceptScore W4232272478C2779375183 @default.
• W4232272478 hasConceptScore W4232272478C2779631663 @default.
• W4232272478 hasConceptScore W4232272478C2780416669 @default.
• W4232272478 hasConceptScore W4232272478C2780950330 @default.
• W4232272478 hasConceptScore W4232272478C4937899 @default.
• W4232272478 hasConceptScore W4232272478C501593827 @default.
• W4232272478 hasConceptScore W4232272478C523546767 @default.
• W4232272478 hasConceptScore W4232272478C54355233 @default.
• W4232272478 hasConceptScore W4232272478C547475151 @default.
• W4232272478 hasConceptScore W4232272478C55493867 @default.
• W4232272478 hasConceptScore W4232272478C71924100 @default.
• W4232272478 hasConceptScore W4232272478C86803240 @default.
• W4232272478 hasConceptScore W4232272478C89423630 @default.
• W4232272478 hasConceptScore W4232272478C94665300 @default.
• W4232272478 hasIssue "Supplement_2" @default.
• W4232272478 hasLocation W42322724781 @default.
• W4232272478 hasLocation W42322724782 @default.
• W4232272478 hasOpenAccess W4232272478 @default.
• W4232272478 hasPrimaryLocation W42322724781 @default.
• W4232272478 hasRelatedWork W2392734635 @default.
• W4232272478 hasRelatedWork W2898816813 @default.
• W4232272478 hasRelatedWork W2990287059 @default.
• W4232272478 hasRelatedWork W3120863683 @default.
• W4232272478 hasRelatedWork W4200348663 @default.
• W4232272478 hasRelatedWork W4200582380 @default.
• W4232272478 hasRelatedWork W4223455524 @default.
• W4232272478 hasRelatedWork W4232272478 @default.
• W4232272478 hasRelatedWork W4306644058 @default.
• W4232272478 hasRelatedWork W4311615639 @default.
• W4232272478 hasVolume "6" @default.
• W4232272478 isParatext "false" @default.
• W4232272478 isRetracted "false" @default.
• W4232272478 workType "article" @default.